Dermata Therapeutics Inc has a consensus price target of $9 based on the ratings of 2 analysts. The high is $14 issued by Brookline Capital on September 21, 2021. The low is $4 issued by Maxim Group on March 23, 2023. The 3 most-recent analyst ratings were released by Maxim Group, Brookline Capital, and Maxim Group on March 23, 2023, September 21, 2021, and September 14, 2021, respectively. With an average price target of $9 between Maxim Group, Brookline Capital, and Maxim Group, there's an implied 420.23% upside for Dermata Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/23/2023 | Buy Now | 131.21% | Maxim Group | Anthony Vendetti | $240 → $60 | Maintains | Buy | Get Alert |
09/21/2021 | Buy Now | 709.25% | Brookline Capital | Kumaraguru Raja | → $3360 | Initiates | → Buy | Get Alert |
09/14/2021 | Buy Now | 420.23% | Maxim Group | Anthony Vendetti | → $2160 | Initiates | → Buy | Get Alert |
The latest price target for Dermata Therapeutics (NASDAQ:DRMA) was reported by Maxim Group on March 23, 2023. The analyst firm set a price target for $4.00 expecting DRMA to rise to within 12 months (a possible 131.21% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Dermata Therapeutics (NASDAQ:DRMA) was provided by Maxim Group, and Dermata Therapeutics maintained their buy rating.
There is no last upgrade for Dermata Therapeutics
There is no last downgrade for Dermata Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dermata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dermata Therapeutics was filed on March 23, 2023 so you should expect the next rating to be made available sometime around March 23, 2024.
While ratings are subjective and will change, the latest Dermata Therapeutics (DRMA) rating was a maintained with a price target of $16.00 to $4.00. The current price Dermata Therapeutics (DRMA) is trading at is $1.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.